Drug Trial Radar · NCT03382964
Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Aug 29, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
120
Actual
Start
Mar 5, 2018
Primary completion
Jul 13, 2018
Study completion Jul 28, 2019
Sponsor
- Lead sponsor
- Valneva Austria GmbHIndustry
- Sponsor type
- Industry
- First posted
- Dec 26, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Randomized, observer-blinded, multicenter, dose-escalation Phase 1 clinical study investigating three dose levels of VLA1553 after a single immunization. 120 study participants will be enrolled into the study to receive three different doses (30 subjects in the low and medium and 60 subjects in the high dose group). Vaccination will be given intramuscularly on Day 0. As safety precaution, the study will begin with enrolment of 20 sentinel subjects in an open-label fashion. Thereafter, subjects will be enrolled in a blinded, randomized manner in the three study arms. A re-vaccination will be given at Month 6 or Month 12 to confirm that a single vaccination will be sufficient to induce high titer neutralizing antibodies and protect subjects from CHIKV viremia. Study participants will be followed up until 13 months after initial vaccination.
Conditions
- Chikungunya
Interventions
VLA1553Biological
I.M. vaccination with a live-attenuated Chikungunya virus (CHIKV) vaccine candidate
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of solicited injection site reactionsTime frame: up to Day 14 after single vaccination
- Severity of solicited injection site reactionsTime frame: up to Day 14 after single vaccination
- Frequency of solicited systemic reactionsTime frame: up to Day 14 after single vaccination
- Severity of solicited systemic reactionsTime frame: up to Day 14 after single vaccination
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Optimal Research, LLC
Huntsville, Alabama
Optimal Research, LLC
Peoria, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.